Forest and Pierre Fabre submit levomilnacipran in the US
This article was originally published in Scrip
Executive Summary
Forest Laboratories has submitted a new drug application (NDA) to the US FDA for levomilnacipran, a serotonin norepinephrine reuptake inhibitor (SNRI) for the treatment of major depressive disorder (MDD) in adults.